Independent Research Audit
BPC-157 AUDIT THE RECORD
30+ years of rodent studies, three human pilots, and a regulatory record that includes FDA Category 2 classification and WADA S0 prohibition. Here is what the peer-reviewed literature actually contains.
The short version
BPC-157 is a synthetic 15-amino acid peptide studied in rodent models for three decades. It is not approved by any regulatory authority for human use. The FDA placed it on a prohibited-compounding list in 2023, and WADA bans it in competitive sport. The published research record is extensive for an unapproved compound — hundreds of indexed animal studies, consistently favorable for treated groups across tendon, gut, and nervous-system injury models — but the human evidence is thin: three small pilot studies, none controlled. This site audits what the peer-reviewed literature actually contains, what regulators have said, and where the limits of the data lie. For a plain account of what people in research-use communities report, and what the safety cautions are, see the effects page.
What Is BPC-157?
BPC-157 — formally Body Protection Compound 157 — is a synthetic 15-amino acid peptide with the sequence GEPPPGKPADDAGLV. It is derived from a partial sequence of a protein found in human gastric juice and has a molecular weight of approximately 1419.5 Da [1]. The compound is sometimes designated PL 14736, PLD-116, or BPC 15 in the research literature, depending on the formulation and trial context.
Four of BPC-157's fifteen residues are proline. That structural feature is significant: proline residues resist proteolytic cleavage, making the peptide unusually stable in gastric conditions relative to most short peptides [1]. This stability property was observed early and supported the use of oral and intragastric dosing routes in a number of animal experiments — a meaningful characteristic in preclinical research design.
The peptide does not correspond to any naturally secreted hormone or growth factor. It is not found circulating in blood at measurable concentrations. Its status in research is that of a synthetic cytoprotective agent — a compound studied for its ability to protect and restore tissue integrity across multiple organ systems in animal models [8].
Some research publications describe it as a 'stable gastric pentadecapeptide,' a label that captures both its gastric origin and its resistance to acid degradation [8]. This is the accurate technical framing. It is not a hormone, not a peptide hormone analog, and not approved for any human therapeutic use by any regulatory authority as of 2025.
What the Research Record Shows
The BPC-157 literature is extensive for an unapproved compound and concentrated: the overwhelming majority of published work originates from a single research group at the University of Zagreb, led by Predrag Sikiric and Sven Seiwerth [11]. Independent replication by separate teams is limited. That concentration of authorship is a documented limitation of the evidence base and is factored into every assessment below.
Within that body of work, the findings are consistent. BPC-157 has been studied across musculoskeletal, gastrointestinal, and neurological models in rats and, in a smaller number of pharmacokinetic studies, in dogs. Across Achilles tendon detachment [1], medial collateral ligament transection [4], myotendinous junction separation [14], gastric ulcer models [5], colocutaneous fistula models [6], spinal cord compression injury [10], and several CNS perturbation paradigms [11], administered BPC-157 consistently outperformed untreated controls on the relevant outcome measures.
On the human side, the record is sparse. As of early 2025, a systematic review of the musculoskeletal literature identified 544 published BPC-157 articles from 1993 to 2024, of which 36 focused on orthopaedic outcomes and only one was a human clinical study [16]. A separate 2025 narrative review confirmed three total published human pilot studies and noted that no major adverse events were reported across those pilots [15].
Those three human pilots include: a Phase I safety study in healthy volunteers (2003, well-tolerated); a Phase II multicenter RCT as PL 14736 for mild-to-moderate ulcerative colitis (Pliva, completed but full results not published as a peer-reviewed paper); and one published human clinical study examining intra-articular injection in 12 patients with chronic knee pain, of whom 7 out of 12 reported relief lasting over 6 months [15].
The standard evaluative statement is this: preclinical evidence across multiple rodent models is consistently favorable; clinical evidence in humans is insufficient to draw conclusions about efficacy or safety in therapeutic contexts.
Regulatory Status: FDA, WADA, DEA
BPC-157 occupies a defined position in the US regulatory landscape, and that position has changed in recent years.
In September 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Category 2 means licensed US compounding pharmacies cannot legally compound BPC-157 for individual patients [15]. The FDA cited insufficient human safety data, potential for immune reactions, and manufacturing impurity concerns as the bases for this classification.
From a WADA perspective, BPC-157 has been listed under Section S0 — Non-Approved Substances — on the Prohibited List since 2022 [15]. S0 covers all pharmacological substances not approved by any regulatory authority for human therapeutic use. The prohibition applies at all times, both in- and out-of-competition. No Therapeutic Use Exemption is available for BPC-157 because no regulatory authority has approved it for any indication. USADA has specifically noted that no safe dose has been established in humans.
BPC-157 is not scheduled under the Controlled Substances Act [15]. It is not a DEA-controlled substance as of 2025. Possession in the United States is not federally criminalized. However, sale as a drug, food, or dietary supplement without FDA approval is unlawful under federal law. The compound exists in a legal gray zone as a research chemical — legal to possess, unlawful to sell as a therapeutic product.
No EMA (European Medicines Agency) or MHRA approval exists for any indication. No active IND (Investigational New Drug application) is publicly listed in the United States as of 2025.
The Audit Verdict
BPC-157 is a legitimate research compound in the specific sense that it has an established molecular identity (sequence GEPPPGKPADDAGLV, MW 1419.5 Da [1]), a reproducible synthetic production pathway, and a substantial peer-reviewed animal research literature published in indexed journals [1][2][3][4][5][6][7][8][9][10][11][12][13][14].
It is not a legitimate therapeutic in any regulatory sense. No human efficacy trial has met the evidentiary bar for regulatory approval. The only Phase II human trial data that exist were never published in peer-reviewed form [8]. FDA Category 2 status prohibits compounding. WADA S0 prohibits use by competitive athletes.
The 'legit' question has a two-part answer. The compound is real, its preclinical findings are real, and the published research is peer-reviewed and indexed. The human evidence is not. Three pilot studies with very small sample sizes, a Phase II trial whose results remain unpublished, and a regulatory record that reflects the FDA's own assessment that sufficient human safety data do not exist — that is the complete ledger as of 2025.
The pages linked below present the evidence without reduction. Every claim cites its source.